NPPA Cuts Cancer Drug Prices by 90%: Keytruda Costly

Q: 1. Which authority revised cancer drug prices in India?

The National Pharmaceutical Pricing Authority (NPPA) revised the prices under the Department of Pharmaceuticals.

Q: 2. When do the revised cancer drug prices take effect?

The revised maximum retail prices take effect across pharmacies nationwide on November 9, 2026.

Q: 3. What is the difference between scheduled and non-scheduled drugs under NPPA rules?

Scheduled drugs belong to the National List of Essential Medicines (NLEM) and have strict ceiling prices set by NPPA. Non-scheduled drugs do not have fixed ceiling prices, but NPPA monitors them and caps their trade margins or annual price increases.

Q: 4. Why did Keytruda's price remain unchanged at ₹2,16,500?

Keytruda is a patented, single-source imported immunotherapy drug. Because its high price stems from the manufacturer's base cost rather than supply-chain markups, a 30 percent trade-margin cap provides minimal reduction.

Q: 5. What requirement does the NPPA order place on drug manufacturers regarding production levels?

Manufacturers must publish updated price lists and maintain existing production levels. They cannot reduce production without prior permission from the NPPA.

Updated: 29 Oct 2026

2 Min Read

NPPA Cuts Cancer Drug Prices by 90%: Keytruda Costly

National Pharmaceutical Pricing Authority (NPPA) has revised the maximum retail prices (MRPs) of 543 cancer drug brands and pack sizes. This regulatory step brings significant financial relief to patients using generic and biosimilar formulations, with price drops exceeding 90 percent on select formulations.

However, high-cost immunotherapy drugs—such as Keytruda (pembrolizumab)—remain listed at ₹2,16,500 per 100 mg vial. The revised pricing framework officially takes effect on November 9, 2026.

Essential Regulatory Concepts:

National Pharmaceutical Pricing Authority (NPPA): An independent statutory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, established in 1997. It enforces price controls under the Drugs (Prices Control) Order (DPCO).
National List of Essential Medicines (NLEM): A priority list of medicines compiled by the Ministry of Health and Family Welfare. Medicines on this list become scheduled formulations, meaning the NPPA directly caps their ceiling prices.
Trade Margin Rationalization (TMR): The regulatory mechanism that limits the profit margin gap between the price to distributor (PTD) and the maximum retail price (MRP). The NPPA capped trade margins at 30 percent for 137 non-scheduled anti-cancer medicines.
Biosimilars vs. Generics: Generics are exact chemical copies of small-molecule synthetic drugs. Biosimilars are highly similar, biotherapeutic copies of complex biological drugs (such as monoclonal antibodies).

Why Single-Source Immunotherapy Drugs Remain Expensive

Despite the broad intervention, 65 high-cost, single-source oncology drugs recorded no price reductions.

Key Factors Behind Unchanged Prices:

High Initial Base Price: The trade-margin cap restricts distributor markups but does not lower the manufacturer’s initial sale price.
Lack of Local Competition: Patented biologicals—including Keytruda (pembrolizumab), Tagrisso, Tecentriq, Darzalex, and Imfinzi—face no domestic generic or biosimilar competition to drive down baseline costs.
Excluded Formulations: Out of 137 target medicines, 27 formulations (including abemaciclib and sotorasib) lacked updated corporate filing data at the time of the order.

Summary Fact Sheet for Quick Revision

Parameter / Metric	Official Regulatory Details
Regulatory Authority	National Pharmaceutical Pricing Authority (NPPA)
Parent Department	Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers
Effective Date	November 9, 2026
Total Formulations Covered	543 brands and pack sizes
Trade Margin Cap Level	30% on 137 non-scheduled anti-cancer drugs
Highest Single Price Drop	Palbopro (Palbociclib) reduced by 93.3%
Unchanged Immunotherapy Landmark	Keytruda (₹2,16,500 / 100 mg vial)

About the author

Girish Kumar

Current Affairs Content Writer

Girish Kumar is a current affairs content writer at Utkarsh Classes, with a decade of experience covering diverse contemporary issues. He develops high-quality study material for various competitive examinations, including UPSC, PSC, Bank PO etc.